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1 2 We excluded people with reported prevalent disease at baseline but cannot exclude the possibility that including those with subclinical or undiagnosed disease at baseline could have influenced the findings. In the manuscript we originally submitted we simply considered two groups of commuters-active and non-active. We tried to minimise the potential contribution of reverse causality by undertaking a sensitivity landmark analysis, which excluded all events occurring in the first year of follow-up. This did not alter the main findings.
In the review process we were asked to consider commuting by cycle and by foot separately and to consider mixed mode commuting. This additional analysis strengthened the paper, but having more groups reduced the number of events in each group, leaving insufficient power to perform the landmark analysis we undertook in the original version. This analysis will be possible in future when more events have accrued. We thought that we had mentioned reverse causality as a limitation in the discussion, but on re-reading realised that we had not. We should have done, and we thank Colquhoun for his valid point.
We adjusted for a comprehensive range of potential confounders in our analyses, but residual confounding is always a possibility in observational studies, which we acknowledge in the paper. Observational data cannot show causality; randomised controlled trials (RCTs) are the gold standard for establishing causality. But RCTs are not always feasible for answering research questions of this nature, owing to the relatively low event rate in the general population. For example, it took 23 years of follow-up in the Da Qing RCT to show that lifestyle intervention reduced risk of mortality from cardiovascular disease and all causes.
